You are here

Medical News Today report that SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).

sandy craine's picture
Submitted by sandy craine on Thu, 27/03/2008 - 11:25am
New Research Gives Additional Therapeutic Tools For Even More Effective And Longer Control Of Chronic Myeloid Leukemia Main Category: Lymphoma / Leukemia Article Date: 25 Mar 2008 Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML). The results of their study will be published the week of March 24th in the Proceedings of the National Academy of Sciences.

New Research Gives Additional Therapeutic Tools For Even More Effective And Longer Control Of Chronic Myeloid Leukemia
Main Category: Lymphoma / Leukemia
Article Date: 25 Mar 2008

Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML). The results of their study will be published the week of March 24th in the Proceedings of the National Academy of Sciences.

Targeted Therapy in Chronic Myeloid Leukemia

sandy craine's picture
Submitted by sandy craine on Sat, 16/02/2008 - 1:47pm
02/06/2008 Elias Jabbour; Jorge E Cortes; Hady Ghanem; Susan O'Brien; Hagop M Kantarjian Abstract Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.


02/06/2008

Elias Jabbour; Jorge E Cortes; Hady Ghanem; Susan O'Brien; Hagop M Kantarjian

Abstract
Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity. Imatinib, the current first-line therapy for CML, induces durable treatment responses in most patients. However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations. With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Randomized trial data suggest that dasatinib treatment is superior to imatinib dose escalation in patients with imatinib resistance. Nilotinib, a recently approved analogue of imatinib, has also demonstrated encouraging treatment responses in patients with imatinib-resistant CML. Other agents (including bosutinib and INNO-406) are in clinical development. With the potential availability of multiple treatment options for patients with CML, it may be possible to tailor treatment according to individual patient or disease characteristics, for example, BCR-ABL mutations. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.

Webcast- "Monitoring and Adherence in CML"

sandy craine's picture
Submitted by sandy craine on Fri, 18/01/2008 - 12:28pm
Summary: Imatinib, or Glivec (Gleevec-USA), is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance.

Summary:
Imatinib, or Glivec (Gleevec-USA), is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance.

Household Exposure to Pesticides and Risk of Childhood Hematopoietic Malignancies: The ESCALE Study (SFCE)

sandy craine's picture
Submitted by sandy craine on Thu, 17/01/2008 - 7:26pm
The study findings strengthen the hypothesis that domestic use of pesticides may play a role in the etiology of childhood hematopoietic malignancies. The consistency of the findings with those of previous studies on AL raises the question of the advisability of preventing pesticide use by pregnant women.

The study findings strengthen the hypothesis that domestic use of pesticides may play a role in the etiology of childhood hematopoietic malignancies. The consistency of the findings with those of previous studies on AL raises the question of the advisability of preventing pesticide use by pregnant women.

Pages